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has recently carried out an exploratory study of a national
program for surveillance of antimicrobial resistance in
France. Dr. Aubry-Damon also collaborates closely with the
French National Reference Center for Antibiotics.  (No photo
available)
Dr. Courvalin is professor at the
Institut Pasteur, where he di-
rects the French National Refer-
ence Center for Antibiotics and
heads the Antibacterial Agents
Unit. Dr. Courvalin specializes in
the genetics and biochemistry of
antibiotic resistance. His re-
search has led to revision of the
description of the natural dis-
semination of antibiotic resis-
tance genes. His laboratory dem-
onstrated that pathogenic bacteria can promiscuously
exchange genetic material conferring antibiotic resistance,
documented that conjugation could account for dissemination
of resistance determinants between phylogenetically remote
bacterial genera, elucidated the transposition mechanism of
conjugative transposons from gram-positive cocci, and
recently, obtained direct gene transfer from bacteria to
mammalian cells.
Surveillance of antibiotic resistance in
human pathogens has long been performed in
France. Existing surveillance relies on national
reference centers dedicated to various bacterial
genera and on networks of volunteer medical
microbiologists, mainly in general hospitals but
also in private laboratories. Regional data (often
initiated at the request of and funded by the
pharmaceutical industry) have been available
since the early 1950s. Because of the major
health problems caused by antibiotic resistance
in the last few years, attempts have been made to
organize a national surveillance program similar
to those being established in other European
countries. Although this update reviews recent
data from France, the representativeness of the
data has not been assessed. In addition, these are
raw data, and their clinical importance remains
to be seen; for example, the contribution of
bacterial isolates to infection or colonization is, in
most instances, unknown.
Evolution of Antibiotic Resistance in
Hospitals
Dissemination of b b b b b-Lactamases in
Gram-Negative Bacilli
In France, b-lactamases and fluoroquinolones
are the most frequently prescribed antibiotics in
Enterobacteriaceae infections. A multicenter
study (14 hospitals) across the country analyzed
the antibiotic susceptibility of 2,507 and 2,312
consecutive, nonrepetitive enterobacteria re-
sponsible for infection in 1996 and 1997,
respectively (1,2). Strains were isolated from
inpatients (86%) in intensive care (ICU) (12%),
surgical (17%), medical (37%), and geriatric (9%)
units. The majority of isolates were from urine
(71%), pus (9%), and bronchopulmonary speci-
mens (8%). Escherichia coli (64%) was isolated
most frequently, mainly in outpatients, whereas
Klebsiella spp. and Enterobacteriaceae with
inducible  b-lactamases predominated in ICUs.
Resistance of E. coli to amoxicillin and
cefotaxime was 47% and 0.5%, respectively. In
1997, the frequency of isolates producing an
extended-spectrum b-lactamase varied by spe-
cies: in Enterobacter aerogenes, 56%; in
Klebsiella pneumoniae, 15%; and in E. coli, 0.5%.
The incidence differed within and between
hospitals. Such strains arise in response to the
selective pressure exerted by use of extended-
spectrum cephalosporins (3); infections with
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such strains have also been associated with
hospitalization in ICUs. Production of
b-lactamases resistant to b-lactam-enzyme
inhibitor combinations in E. coli was approxi-
mately 3.5% (2). Susceptibility to fluoroquinolones
was high (66%-97% ciprofloxacin-susceptible)
except in E. aerogenes and Serratia marcescens
(35%-52% ciprofloxacin-susceptible) (1).
The organisms most frequently isolated in
ICUs in 1995 belonged to the family Enterobacte-
riaceae (59%) and Pseudomonas aeruginosa
(25%) (4). In 1997, 1,362 nonrepetitive
P. aeruginosa (5% of all clinical isolates) were
collected in 13 teaching hospitals (5). The lowest
rates of susceptibility to ceftazidime (<75%),
amikacin (70%), and ciprofloxacin (65%) were
observed with serotype 12 (the fourth main
serotype). Among penicillinase-producing strains,
the percentages of resistance to amikacin and
ciprofloxacin were 80% and 93%, respectively;
these figures were substantially higher in
b-lactam-resistant  P. aeruginosa than in
susceptible strains.
Spread of Methicillin-Resistant and
Gentamicin-Susceptible Staphylococcus
aureus
Methicillin-resistant  S. aureus (MRSA) is
one of the most frequent nosocomial pathogens in
France as in the rest of the world. Surveys
conducted in hospitals in Paris and surroundings
found that MRSA decreased from 42% in 1992 to
37% in 1997 and that the incidence of MRSA
colonization-infection (approximately 0.65 per
100 admissions) also decreased after national
recommendations against dissemination of
multidrug-resistant bacteria were implemented
(6,7). However, a survey of 26 geographically
representative hospitals found that the inci-
dence of gentamicin-susceptible MRSA progres-
sively increased because of the presence of a
predominant clone (H. Lelièvre, G. Lina, M.E.
Jones, et al., unpub. obs.). The epidemiologic
situation in France is complex. The endemic
aminoglycoside-resistant MRSA strain persisted
while new clones became endemic in hospitals,
perhaps after changes in the use of
aminoglycosides (decrease of gentamicin and
increase of amikacin consumption) (8). The first
vancomycin-intermediate S. aureus was isolated
in a French hospital in 1995; no other cases of
MRSA with reduced susceptibility to vancomy-
cin have been reported (9).
Most Frequent Macrolide-Resistance
Mechanisms among Staphylococci
Over 3 weeks in 1995, 607 staphylococci were
collected in 32 hospitals (10). Of these, 45.5% of
the S. aureus and 54% of the coagulase-negative
staphylococci were resistant to methicillin, and
71.5% of MRSA were resistant to macrolides. Of
these MRSA strains, 75% were constitutively
resistant, whereas 76% of MSSA were inducibly
resistant. A similar distribution (61% vs. 27.5%)
was observed among coagulase-negative staphy-
lococci. Resistance to at least one of the
macrolide, lincosamide, and streptogramin
antibiotics (88%) was due to the presence of the
ermA and ermC genes, which confer resistance
by modifying the ribosomal target. The ermA
gene was more common in MRSA (57.6%) than in
MSSA (5.6%), where ermC was predominant
(20.1%).  ermC was also common among
methicillin-susceptible coagulase-negative sta-
phylococci (14%). Only a few strains had the
ermB gene, which is found in animal strains.
Macrolide resistance by efflux due to acquisition
of the msrA gene was more prevalent in
coagulase-negative staphylococci (14.6%) than in
S. aureus (2.1%). The incidence of lincomycin-
resistant but macrolide- and streptogramin-
susceptible staphylococci was low: 0.2% in
S. aureus and 4.6% in Staphylococcus epidermidis
(11). The prevalence of pristinamycin-resistant
(and also most probably quinupristin/dalfopristin-
resistant) strains remained low because of the
low incidence of resistance to streptogramins
type A (pristinamycin has limited use in France).
Dissemination of Resistance in the
Community
Effect of Antibiotics on Oropharyngeal Flora
Antibiotic Resistance in Streptococcus
pneumoniae
The National Reference Center for Pneumo-
cocci determined the susceptibility to antibiotics
of 2,837 S. pneumoniae isolated in 1997. The
incidence of S. pneumoniae with reduced
susceptibility to penicillin G increased from 3.8%
in 1987 to 48% in 1997 (12). Whereas 53% of all
strains were resistant to macrolides, 80% of
penicillin-resistant strains were macrolide-
resistant; 15% of all strains (versus 51% of
penicillin-resistant strains) were resistant to
tetracycline, and 10% (versus 66%), respectively,317 Vol. 5, No. 3, MayJune 1999 Emerging Infectious Diseases
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were resistant to trimethoprim-sulfamethoxazole
(F. Goldstein et al., unpub. data). According to a
1997 survey of 18 regional laboratories in France
(11,757 strains collected), 27% had intermediate
levels of resistance to penicillin G, and 13.5%
were fully resistant. The rates varied consider-
ably by region (highest in southwest and central
France), age (highest [37.4% penicillin
G-intermediate and 21.5% resistant] in children
<16 years old), and specimen source (highest in
middle ear and sinus specimens) (13).
Resistance to Macrolides in b b b b b-Hemolytic
Streptococci
In 1995, a national survey in 98 hospitals of
invasive infections due to Streptococcus pyogenes
found that 5.2% to 9.8% of the strains isolated
from blood were erythromycin-resistant
(A. Bouvet, pers. comm.) (14).
Vaccination against and Resistance in
Haemophilus influenzae Type b
To monitor the trends in H. influenzae
meningitidis and the prevalence of resistance,
the National Reference Center conducted a
survey of approximately 80 hospitals (15). Since
vaccination for Hib invasive infections began in
1993, the percentage of capsulated isolates has
decreased 5% per year. Moreover, resistance to
antimicrobial drugs decreased among Hib and
increased among noncapsulated strains isolated
from upper and lower respiratory tract
infections. The percentage of b-lactamase-
producing  H.  influenzae increased progressively
from 22% in 1992 to 35% in 1997, with a similar
evolution for kanamycin resistance. Tetracycline
and chloramphenicol resistance remained stable
in 1997less than 10% and 2%, respectively
(15,16).
Antibiotic Resistance in Neisseria
meningitidis
Meningococcal resistance to antibiotics is
emerging in France. The incidence of
N. meningitidis with reduced susceptibility to
penicillin G (MICs from 0.125 mg/L to 1 mg/L)
increased from less than 1% in 1991 to 18% in
1996  (17,18). The strains belonged to various
serogroups; most belonged to serogroup B, none
produced a b-lactamase, and all were susceptible
to cefotaxime and ceftriaxone. Resistance to
rifampin, used for prophylaxis of secondary cases
in France, remained low (0.02% in 1996).
Effect of Antibiotics on Digestive Flora
Antimicrobial Resistance in
Helicobacter pylori
Susceptibility testing of H. pylori from 535
patients with a positive CLO test was performed
in 1997 (19). Depending on the method, the
percentages of clarithromycin resistance (disk-
agar diffusion or MIC determination by agar
dilution) and metronidazole resistance
(breakpoint method at 8 mg/L or MIC
determination) varied from 14.3% (95% confi-
dence interval [CI] 11.5-17.6) to 14.0% (95% CI
11.2-17.3) and from 30.5% (95% CI 25.6-34.5) to
23.6% (95% CI 20.1-27.5), for the two antibiotics,
respectively. No resistance to amoxicillin was
observed.
Fluoroquinolone Resistance in
Campylobacter and Salmonella Hadar
The evolution of antimicrobial resistance in
Campylobacter jejuni and C. coli is worrisome.
Between 1986 and 1997, 2,713 strains of C. jejuni
(68% of total Campylobacter isolates) were
isolated from stool (94%) and blood (4%) and
studied (20). Between 1993 and 1997,
fluoroquinolone resistance increased from 7.4%
to 32% in C. jejuni and from 11.8% to 52% in
C. coli.  The high resistance rate to quinolones
makes them ineffective in therapy of
Campylobacter infections. These resistance rates
are similar to those in other countries (e.g.,
Spain, the United Kingdom) (21,22). However,
the prevalence of macrolide-resistant strains
remains low (3.6%). The high incidence of
multidrug-resistant Salmonella Typhimurium
DT104 (12 atypical), with 82% resistance to
ampicillin, streptomycin, sulphonamide, tetra-
cycline, and chloramphenicol, is the most serious
epidemiologic problem of the last decade in
France (23). The incidence of Salmonella Hadar
is increasing, and the percentages of amoxicillin-
and fluoroquinolone-resistant strains in 1997
were 72% and 75%, respectively. Fluoroquinolone
resistance had not been observed before 1987 in
France, Spain, and the United Kingdom. This
was before concomitant introduction of
ciprofloxacin into clinical use and enrofloxacin
into veterinary use (in particular in the poultry
industry) in the late 1980s. More than 50% of
C. jejuni and S. Hadar, the most frequent
serotype associated with poultry, are now
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The situation is different in Sweden, where
fluoroquinolones are not readily available.
Therefore, guidelines for the prudent use of
antibiotics (in prophylaxis or therapy) should be
developed that respect the indigenous flora of
humans and animals.
New Types of Resistance in Enterococci
The increase in the incidence of glycopep-
tide-resistant enterococci (GRE) isolated from
hospitalized patients throughout the United
States has not been observed in France. A
multicenter study in 1993 showed a very low
incidence of GRE: 0.2% among 251 enterococcal
clinical isolates and 7.5% among Enterococcus
faecium  (24). Study of 24 ICUs in 1994
determined that the prevalence of GRE
colonization in patients fecal flora was
approximately 2%, 30% of which had been
present at admission. No nosocomial infection
due to GRE was observed (25). GRE have been
identified in human food of animal origin (40% of
GRE were isolated from uncooked meat) in a
French study conducted in military cafeterias in
1997 (26). Thus, food may represent a major
source of human colonization with GRE in
France. GRE strains isolated in France were also
resistant to ampicillin, tetracycline, and
macrolides. However, the percentage of high
resistance levels to gentamicin among GRE was
comparable to that among glycopeptide-suscep-
tible enterococci.
Antibiotic Resistance in
Bacteroides fragilis
Studies of antibiotic resistance in anaerobic
pathogens indicate stability of resistance to
carbapenems (imipenem) and nitroimidazole
antibiotics (27,28). In 1998, fewer than 2% of all
B. fragilis from 39 hospitals were resistant to
metronidazole (MICs >8 mg/L), and the number
of imipenem-resistant strains remained low.
However, this gene reservoir requires surveil-
lance of resistance in B. fragilis infections
because of the use of these antibiotics in therapy.
Other Bacteria
Antibiotic Resistance in
Neisseria gonorrhoeae
The number of N. gonorrhoeae strains
identified by the National Reference Centre for
Sexually Transmitted Diseases fell sharply from
1986 to 1990 (by 81%) and more slowly from 1990
until 1999 (by 55%) (29). The number of anorectal
gonococcal infections reached a plateau from
1995 to 1997 but increased again in 1998, mostly
in the Paris/Ile-de-France region (V. Goulet,
P. Sednaoui, et al., unpub. data). An increasing
percentage of N. gonorrhoeae displayed dimin-
ished sensitivity to penicillin G and to
tetracycline. In 1997, 15% and 30% of
N. gonorrhoeae were resistant to penicillin G
(MIC  ³  2 mg/L) and tetracycline (MIC  2 ³ mg/L
and < 16 mg/L), respectively, by chromosomal
mutation. In contrast, the percentage of strains
with plasmid-mediated resistance to penicillins
and tetracycline has remained stable at
approximately 15% since 1994. No ceftriaxone,
spectinomycin, or ciprofloxacin resistance was
found until 1997, when the first ciprofloxacin-
resistant strains (MIC=1 mg/L) were isolated.
Conclusions
Antibiotic resistance trends in France are for
the most part similar to trends in other European
countries but with some peculiarities. For
instance, fluoroquinolone resistance in Salmo-
nella spp. and Campylobacter spp. is a problem
throughout Europe. However, methicillin resis-
tance in Staphylococcus is more common in
France than in the Scandinavian countries,
although it has started to decrease because of
reinforcement of hygiene measures since 1992.
Also, heavy use of 16-membered macrolides has
selected for resistance in gram-positive cocci by
ribosomal modification rather than by efflux. In
pneumococci, decreased susceptibility to penicil-
lins is as common in France as in Spain, but the
incidence of resistance to macrolides is the
highest in Europe. The public health problems
caused in France by bacterial resistance to
antibiotics are clearly distinct from those in
North America. The incidence of enterobacteria
producing extended-spectrum b-lactamases and
glycopeptide-resistant enterococci remains rather
low in France, as in most other European
countries. In the United States, the high
incidence of nosocomial GRE infections is
probably caused by the heavy nosocomial use of
vancomycin, particularly in hematology wards
and for the prevention of colitis due to
Clostridium difficile. In contrast, no intestinal
carriage of such strains is found in the general
population. The situation in Europe mirrors that
in the United States. In Europe, the prevalence319 Vol. 5, No. 3, MayJune 1999 Emerging Infectious Diseases
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of nosocomial GRE infections remains low, but
colonization of the population is substantial,
possibly because of the use of a vancomycinlike
antibiotic (avoparcin) as an animal food additive.
This example stresses the need for a
multidisciplinary approach to surveillance of
bacterial resistance to antibiotics.
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